Intellia Therapeutics Inc at Chardan Genetic Medicines Conference Transcript
All right, let's get started. So it's now my pleasure to introduce Dr. John Leonard, President and CEO of Intellia Therapeutics. The format for this session is a fireside chat that we can open to an audience Q&A at the end. John, thank you so much for joining us today.
Questions & Answers
So Intellia has shared data recently from its two clinical stage in-vivo editing programs. Before we talk about those in more detail, can you give us a brief overview of where the company is now and go over the near-term catalysts and value drivers?
Sure. Good morning. Good to see you in person.
Yeah. So you'll remember we're a full-spectrum genome editing company. And so we think about the company in those terms, which means in-vivo side of the company, the ex-vivo side, as well as our platform.
And so on in-vivo side, as you mentioned, we have a couple of clinical
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
